Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 2/20 | 0.36 |
| ▸ | REN | P00797 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17144784 | 1.00 | L3MBTL1 (0.42) | L3MBTL1HTR2CSLC6A4JAK2JAK1 | |
| SCHEMBL5565367 | 0.81 | RIPK1 (0.41) | SLC6A4KMT2AAKT1MEN1CTSL | |
| SCHEMBL17138254 | 0.81 | L3MBTL1 (0.43) | L3MBTL1HTR2CSLC6A4JAK2JAK1 | |
| SCHEMBL5559510 | 0.79 | AKT1 (0.39) | SLC6A4KMT2AAKT1MEN1CTSL | |
| SCHEMBL17138236 | 0.78 | CTSL (0.47) | KMT2AMEN1CTSLCTSBCTSS | |
| SCHEMBL17138232 | 0.78 | CTSL (0.47) | KMT2AMEN1CTSLCTSBCTSS | |
| SCHEMBL18810468 | 0.76 | USP2 (0.38) | SLC6A4KMT2AAKT1MEN1CTSL | |
| SCHEMBL5658170 | 0.76 | USP2 (0.38) | SLC6A4KMT2AAKT1MEN1CTSL | |
| SCHEMBL18522980 | 0.76 | USP2 (0.38) | SLC6A4KMT2AAKT1MEN1CTSL | |
| SCHEMBL17138279 | 0.75 | L3MBTL1 (0.44) | L3MBTL1SLC6A4SLC18A3KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158307-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | ACES Pharma Inc. (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160158307-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | ACES Pharma Inc. (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160158307-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | ACES Pharma Inc. (US) | 2016-06-09 | — | — | US | disclosed |
| US-9260478-B2 | Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis | HU SHANGHUI (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260478-B2 | Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis | HU SHANGHUI (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260478-B2 | Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis | HU SHANGHUI (US) | 2016-02-16 | — | — | US | disclosed |
| WO-2015154029-A1 | POTENT AND EFFICIENT CYTOTOXIC PEPTIDES AND ANTIBODY-DRUG CONJUGATES THEREOF | ACES Pharma Inc. (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015154029-A1 | POTENT AND EFFICIENT CYTOTOXIC PEPTIDES AND ANTIBODY-DRUG CONJUGATES THEREOF | ACES Pharma Inc. (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20150284425-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | ACES Pharma Inc. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284425-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | ACES Pharma Inc. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284425-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | ACES Pharma Inc. (US) | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158307-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | NGLY1, VIP, DNPEP | L3MBTL1 261/4885HTR2C 4758/4885SLC6A4 3250/4885 |
| US-20150284425-A1 | Potent and Efficient Cytotoxic Peptides and Antibody-Drug Conjugates thereof and Their Synthesis | NGLY1, VIP, DNPEP | L3MBTL1 261/4885HTR2C 4758/4885SLC6A4 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.